Log in to search using one of your social media accounts:

 

MS Drug Works in Kids
(MedPage Today) -- Top-line results suggest good safety profile for fingolimod in pediatric MS (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - September 5, 2017 Category: Neurology Source Type: news

Bone Health Drug Inhibits Mesothelioma Tumor Growth
A drug used to treat bone disease and high blood calcium levels may carry benefits as part of a combination treatment for malignant pleural mesothelioma, a recent study concluded. Researchers at the University of Alabama at Birmingham Comprehensive Cancer Center conducted a pilot study testing the effects of zoledronic acid — a bisphosphonate, or bone health drug, marketed as Reclast and Zometa — against a small group of patients with unresectable pleural mesothelioma. The study, published in the June edition of Lung Cancer: Targets and Therapy journal, was a follow-up to preclinical research showing zoledron...
Source: Asbestos and Mesothelioma News - July 20, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: bone disease treatment keytruda mesothelioma treatments Muhammad Omer Jamil reclast treating malignant pleural mesothelioma University of Alabama at Birmingham Comprehensive Cancer Center Zoledronic acid zometa Source Type: news

Fingolimod during pregnancy: Is it safe?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - June 7, 2017 Category: Consumer Health News Source Type: news

Multiple Sclerosis Drug Effectively Stops Mesothelioma Cells
Research from the University of Hawaii Cancer Center shows an immune suppression drug already used to treat multiple sclerosis could become an effective tool against malignant mesothelioma. The drug, fingolimod (FTY720), showed an ability to shrink mesothelioma tumors cells in the laboratory and in animal models without causing substantial side effects. Fingolimod, which is derived from the fungus isaria sinclairii, also is being studied for potential use with cervical, breast, lung and prostate cancers. This was the first study of its effectiveness with mesothelioma. The Journal of Translational Medicine published the res...
Source: Asbestos and Mesothelioma News - May 11, 2017 Category: Environmental Health Authors: Matt Mauney Tags: anti-cancer effect on mesothelioma cells Dr. Haining Yang fingolimod mesothelioma FTY720 immune suppression drugs isaria sinclairii Journal of Translational Medicine mesothelioma life expectancy multiple sclerosis drugs Repurposing drugs Source Type: news

Novartis real-world data at AAN confirms benefit of Gilenya ® on four key measures of disease activity in relapsing MS
Novartis today announced data from the Phase IV Multiple Sclerosis and clinical outcome and MRI in the US (MS-MRIUS) study, which confirmed the effectiveness of Gilenya® (fingolimod) in the real-world setting, supporting previous findings from Phase III trials[1],[2]. (Source: World Pharma News)
Source: World Pharma News - April 24, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Glenmark gets tentative nod from USFDA for Fingolimod capsules
"Glenmark Pharmaceuticals USA has been granted tentative approval by the USFDA for Fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 20, 2017 Category: Pharmaceuticals Source Type: news

Study sheds light on the biology of progressive form of multiple sclerosis
(Brigham and Women's Hospital) A research team led by scientists from Brigham and Women's Hospital has revealed how an FDA-approved drug works in the central nervous system in mice to suppress chronic inflammation. The drug, known as FTY720 (or Fingolimod) interferes with signals sent through sphingosine-1-phosphate receptors, and appears to reduce the pathogenic activities of astrocytes. The findings suggest the treatment may hold promise for a progressive and difficult-to-treat form of multiple sclerosis (MS) known as secondary progressive MS (SPMS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2017 Category: Global & Universal Source Type: news

How to empower your health and wellness customers
Vince Schaller, Managing Director, Schawk (Los Angeles) “Ask your doctor if it’s right for you.” That advice, familiar in the U.S. ever since direct-to-consumer pharmaceutical advertising became legal nearly 20 years ago, is still sound. But today, consumers are increasingly asking themselves, before they even schedule a doctor’s appointment, “What are the right choices for me?” Call it the increasing consumerism of health and wellness. Or, in the words of Kristin Hambelton, one of many CMOs who are bringing traditional marketing strategies to healthcare-oriented enterprises, call it the...
Source: Mass Device - February 2, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Blog Schawk Source Type: news

ANA: Fingolimod Modulates RAGE in MS (CME/CE)
(MedPage Today) -- Pro-inflammatory markers in the serum reduced as anti-inflammatory molecules increase (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - October 19, 2016 Category: Radiology Source Type: news

AMNOG and the German Reforms: What Will Change?
Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial opportunities and has an important position as an international reference country to 17 marketsi.The implementation of AMNOG in 2011 sought to reduce drug prices and relieve the healthcare budget, yet financial pressure remains, particularly from high-priced novel agents in Hepatitis C, and Oncology. As a result, in July 2016, the German Ministry of Health put forth a legislative proposal to reduce pharmaceutical spending and perceived exorbitant prices, as well as improve the A...
Source: EyeForPharma - October 3, 2016 Category: Pharmaceuticals Authors: Preeti Patel and Sophie Schmitz Source Type: news

Alemtuzumab Comparison Data Show Some Surprises Alemtuzumab Comparison Data Show Some Surprises
New observational propensity-matched data on head-to-head comparisons of alemtuzumab with beta-interferon, fingolimod, and natalizumab show some unexpected findings.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 29, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Registry Data: Lemtrada More Effective than Competing MS Tx
(MedPage Today) -- Better than fingolimod or interferon; comparable to natalizumab (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 17, 2016 Category: Journals (General) Source Type: news

ECTRIMS: Rituximab Beats MS Drugs in Swedish Registry Study (CME/CE)
(MedPage Today) -- Finds survival advantage for rituximab over fingolimod and natalizumab (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - September 16, 2016 Category: Consumer Health News Source Type: news

Multiple Sclerosis May Rebound When Patients Stop Fingolimod Multiple Sclerosis May Rebound When Patients Stop Fingolimod
In this viewpoint, Dr Barclay discusses a series of five patients with rebound whose cases were consistent with others in the literature.Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 19, 2016 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Long-term Treatment With Fingolimod in MSLong-term Treatment With Fingolimod in MS
The results of this study support a continued beneficial effect of long-term fingolimod therapy in patients with relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Receptor variation influences fingolimod efficacy in mouse multiple sclerosis models
(JCI Journals) In this issue of JCI Insight, May Han of Stanford University and colleagues tested the hypothesis that genetic variants of the cell surface receptor that responds to S1P, S1PR1, may influence the efficacy of fingolimod. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 16, 2016 Category: Global & Universal Source Type: news

Real-world data favor dimethyl fumarate, fingolimod for MS
VANCOUVER – Dimethyl fumarate and fingolimod appear to have an edge over other disease-modifying therapies for multiple sclerosis (MS) in real-world practice, according to a comparative effectiveness... (Source: Clinical Neurology News)
Source: Clinical Neurology News - June 14, 2016 Category: Neurology Source Type: news

Real-world data favor dimethyl fumarate, fingolimod for MS
VANCOUVER – Dimethyl fumarate and fingolimod appear to have an edge over other disease-modifying therapies for multiple sclerosis (MS) in real-world practice, according to a comparative effectiveness... (Source: Family Practice News)
Source: Family Practice News - June 14, 2016 Category: Primary Care Source Type: news

Relapses Rebound in Patients With MS Stopping FingolimodRelapses Rebound in Patients With MS Stopping Fingolimod
As seen with natalizumab, a new study shows patients may experience rebound in relapses after stopping fingolimod. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 12, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Real risk of rebound syndrome following fingolimod cessation for MS
Rebound syndrome following cessation of fingolimod for multiple sclerosis occurs at a clinically relevant rate, shows research, prompting the need for further study on how best to sequence and discontinue such drugs. (Source: MedWire News)
Source: MedWire News - May 4, 2016 Category: Consumer Health News Tags: Multiple sclerosis Source Type: news

Patients May Rebound After Stopping Gilenya (CME/CE)
(MedPage Today) -- Severe rebound syndrome seen in 10% of cases after discontinuation (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - May 4, 2016 Category: Neurology Source Type: news

Fewer new lesions, side effects differentiate fingolimod from dimethyl fumarate
VANCOUVER – Multiple sclerosis patients discontinued treatment and relapsed earlier with dimethyl fumarate (Tecfidera) than with fingolimod (Gilenya), and had more gadolinium-enhancing lesions at 12... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 28, 2016 Category: Neurology Source Type: news

Rituximab outperforms fingolimod after natalizumab switch
Rituximab is more effective and better tolerated than fingolimod for patients with multiple sclerosis needing to switch from natalizumab due to JC-virus antibody positivity, research suggests. (Source: MedWire News)
Source: MedWire News - April 26, 2016 Category: Consumer Health News Tags: Multiple sclerosis Source Type: news

Rituximab is superior to fingolimod for certain patients with multiple sclerosis
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab. The study included patients infected with JC virus, which is present in approximately 50% of the general population. While the virus generally causes no problems under normal circumstances, it can cause progressive multifocal leukoencephalopathy (PML), a serious demyelinating disease of the brain, in patients with immune deficiencies due to disease or immunosuppressant drugs. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 21, 2016 Category: Science Source Type: news

Fingolimod Easier to Swallow Than Dimethyl Fumarate?Fingolimod Easier to Swallow Than Dimethyl Fumarate?
Patients with multiple sclerosis are more likely to discontinue dimethyl fumarate than fingolimod after 2 years or less, largely because of tolerability issues, a real-world study has found. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 20, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Rituximab bests fingolimod in MS patients switching from natalizumab
For patients with relapsing-remitting multiple sclerosis (RRMS) switching to other therapies due to positive JC virus serology, treatment with rituximab resulted in a lower rate of clinical relapse... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 4, 2016 Category: Neurology Source Type: news

What Genetics are Associated with Multiple Sclerosis?
Discussion Multiple sclerosis (MS) is “a chronic degenerative, often episodic disease of the central nervous system marked by patchy destruction of the myelin that surrounds and insulates nerve fibers, usually appearing in young adulthood and manifested by one or more mild to severe neural and muscular impairments, as spastic weakness in one or more limbs, local sensory losses, bladder dysfunction, or visual disturbances.” It is a chronic disease and therefore symptoms must occur more than once. The first episode is called an acute demyelinating attack. Fifteen to forty-five percent of children with their first...
Source: PediatricEducation.org - April 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

FDA Drug Safety Communication: Safety review of a reported death after the first dose of Multiple Sclerosis drug Gilenya (fingolimod)
[12-20-2011] The U.S. Food and Drug Administration (FDA) has received a report of a patient with multiple sclerosis (MS) who died within 24 hours of taking the first dose of Gilenya (fingolimod). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 1, 2016 Category: Drugs & Pharmacology Source Type: news

Brain atrophy may be a clinically relevant measure in PPMS: Data from INFORMS
NEW ORLEANS – The recently published results of the INFORMS multicenter, double-blind, placebo-controlled parallel-group study (NCT00731692) that compared the efficacy of fingolimod in slowing... (Source: Clinical Neurology News)
Source: Clinical Neurology News - February 26, 2016 Category: Neurology Source Type: news

Fingolimod improved gait impairment in small study
NEW ORLEANS – Treatment with fingolimod improved gait impairment in treatment-naive multiple sclerosis (MS) patients and those on a previous first-line therapy in a small, single-center... (Source: Clinical Neurology News)
Source: Clinical Neurology News - February 26, 2016 Category: Neurology Source Type: news

INFORMS Published: Fingolimod Fails in Primary Progressive MS INFORMS Published: Fingolimod Fails in Primary Progressive MS
Full details of the INFORMS trial have confirmed that the multiple sclerosis drug fingolimod did not slow progression of disability or brain volume loss vs placebo in the primary progressive form of the disease. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 19, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Recomendaciones modificadas para observación cardiovascular y uso del medicamento Gilenya (fingolimod) para la esclerosis múltiple
El lunes, 14 de mayo del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) anunció que ha concluido su evaluación de un informe sobre un paciente que murió después de la primera dosis del medicamento Gilenya (fingolimod) para la esclerosis múltiple. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news

New EMA Advice for PML Prevention With Fingolimod in MSNew EMA Advice for PML Prevention With Fingolimod in MS
The European Medicines Agency recommends evaluating patients for progressive multifocal leukoencephalopathy and for basal cell carcinoma before and during treatment with fingolimod (Gilenya). News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 19, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

No Conclusions About MS Drug Superiority (CME/CE)
(MedPage Today) -- Two cohort studies give opposing views of natalizumab versus fingolimod efficacy (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 9, 2015 Category: Neurology Source Type: news

Fingolimod May Protect Neurons from Degeneration (CME/CE)
(MedPage Today) -- Effect appears independent of main mechanism of action in MS (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 5, 2015 Category: Infectious Diseases Source Type: news

Disease modifying drugs
A Cochrane review of disease modifying drugs for relapsing MS found that the best at reducing relapse in the first two years of treatment were alemtuzumab, mitoxantrone, natalizumab and fingolimod. The best at reducing the build up of disability in the same period were mitoxantrone, alemtuzumab, and natalizumab. The review criticises the lack of long-term evidence for efficacy and side effects. MS News Today Disease modifying drugs for relapsing MS - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - September 21, 2015 Category: Neurology Source Type: news

Switching From Natalizumab to Fingolimod in RRMSSwitching From Natalizumab to Fingolimod in RRMS
This study aims to improve our understanding of drug-induced immune changes and potential disease exacerbation during switch-over from natalizumab to fingolimod in treatment of RRMS. BMC Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 31, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

NeuroBreak: Trendy Neurotransmitters, Gilenya PML
(MedPage Today) -- News and commentary from the worlds of neurology and neuroscience (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 25, 2015 Category: Psychiatry Source Type: news

Third Case of PML With Fingolimod (Gilenya) in MS Third Case of PML With Fingolimod (Gilenya) in MS
Novartis reports a third case of progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with fingolimod. News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 18, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Fingolimod (Gilenya) and PML
A third case of the brain infection PML has been reported in someone taking fingolimod. This person had not been taken immune suppressing drugs for MS, but had had chemotherapy and radiotherapy for cancer. Novartis Fingolimod (Gilenya) - A to Z of MS PML (Progressive multifocal leukoencephalopathy) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - August 16, 2015 Category: Neurology Source Type: news

PML risk with Gilenya prompts update to US prescribing information
The FDA has announced that it will update the information for Gilenya (fingolimod) after two possible cases of PML in people with MS taking this disease modifying drug in the USA. (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - August 5, 2015 Category: Neurology Source Type: news

FDA Warns of Fingolimod PML Cases
(MedPage Today) -- Neither patient had been on a previous immunosuppressive agent (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - August 5, 2015 Category: Neurology Source Type: news

MS Drug Fingolimod Gets Label Update to Include PML Cases (FREE)
By the Editors One person has been diagnosed with definite progressive multifocal leukoencephalopathy (PML), and another person … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 5, 2015 Category: Primary Care Source Type: news

FDA Warns of PML Risk With Fingolimod (Gilenya) in MS FDA Warns of PML Risk With Fingolimod (Gilenya) in MS
An FDA drug safety alert describes two cases of PML, one confirmed and one probable, the first among patients with MS not at risk due to previous immunosuppressive therapy. Information on the cases will be added to the label. News Alerts (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 4, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA to revise Novartis' Gilenya label to reflect brain infection risk
(Reuters) - The U.S. Food and Drug Administration said it will update the label of Novartis AG's multiple sclerosis drug, Gilenya, after cases of serious brain infections were linked with its use. (Source: Reuters: Health)
Source: Reuters: Health - August 4, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Gilenya (fingolimod): Drug Safety Communication - FDA Warns About Cases of Rare Brain Infection
Cases of PML in two patients with no prior exposure to immunosuppressant drugs. (Source: FDA MedWatch)
Source: FDA MedWatch - August 4, 2015 Category: American Health Source Type: news

Fingolimod in relapsing remitting multiple sclerosis: Indication of added benefit in certain patients
Based on new analyses conducted by the drug manufacturer, an advantage can be determined in two instead of only one patient group for the use of Fingolimod in relapsing remitting multiple sclerosis. There are now indications instead of a hint. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 6, 2015 Category: Science Source Type: news

Fingolimod extension study
Results after four and half years show that people who started in the beta interferon arm had fewer relapses and less MRI activity after they had switched to fingolimod. MS News Today Disease modifying drugs for relapsing remitting MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 28, 2015 Category: Neurology Source Type: news

Timing the switch from Tysabri to Gilenya
A study has been published showing that a shorter washout time when changing from treatment with natalizumab (Tysabri) to fingolimod (Gilenya) reduces the risk of relapse. MS Research Australia Natalizumab (Tysabri) - A to Z of MS Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 8, 2015 Category: Neurology Source Type: news